• 知识
  • 视频
  • 社区
  •  首页
政策法规
  •  国内药监
  •  FDA
  •  EU
  •  PIC/S
  •  WHO
  •  ICH
  •  MHRA
  •  PMDA
  •  TGA
研发注册
  •  概览
  •  监管动态
  •  研究专题
生产质量
  •  概览
  •  监管动态
  •  各国GMP
  •  中国GMP
  •  中国GMP指南
  •  GMP对比
  •  检查缺陷
  •  研究专题
主题词库
  •  主题词库
帮助中心
  •  帮助中心
关于识林
  •  识林介绍
  •  识林FAQs
  •  功能介绍
  •  团队诊断
  •  联系我们
登录
  •  登录
  •  注册
替换
查找内容:
替换为:
全部替换
插入链接
链接网址:
链接显示标题:
请选择网址类型
点我插入链接
插入文件
文件名称:
文件显示标题:
请选择文件类型
点我插入文件
发现错误 发表观点

原文内容

反馈意见

提交 正在提交..... 反馈历史

复制下面的地址分享给好友

确定 正在提交.....
train

你好,

关闭
提交 重做 重新开始 关闭
跳转
  • 新建同级
  • 新建子级
  • 删除
  • 重命名
选择收藏夹
新建收藏夹
公开

取消 确定

1. 基本信息
姓名:
企业:
职位:
联系方式:
邮箱:
2. 请在此填写您的问题,我们将优先安排答疑
提交

报名成功!
课程观看链接如下:
请添加课程助理微信,获得更多信息:
确认
确定
取消 确认

  • 知识
  • 视频
  • 社区
  • 政策法规
    • 国内药监
    • FDA
    • EU
    • PIC/S
    • WHO
    • ICH
    • MHRA
    • PMDA
    • TGA
  • 研发注册
    • 概览
    • 监管动态
    • 研究专题
  • 生产质量
    • 概览
    • 监管动态
    • 各国GMP
    • 中国GMP
    • 中国GMP指南
    • GMP对比
    • 检查缺陷
    • 研究专题
  • 主题词库
  • 帮助中心
  • 关于识林
    • 识林介绍
    • 识林FAQs
    • 功能介绍
    • 团队诊断
    • 联系我们
  • 30天免登录

    忘记密码?

识林

FDA警告用于治疗癫痫的gabapentin和pregabalin可能引起严重的呼吸问题

首页 > 资讯 > FDA警告用于治疗癫痫的gabapentin和pregabalin可能引起严重的呼吸问题

页面比对

出自识林

FDA警告用于治疗癫痫的gabapentin和pregabalin可能引起严重的呼吸问题
Gabapenti
页面比对
笔记

2020-01-02 FDA

跳转到: 导航, 搜索

FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR)

Listen

Welcome to the FDA Drug Safety Podcast for health care professionals from the Division of Drug Information. On December 19, 2019 FDA is warning that serious breathing difficulties may occur in patients using gabapentin (brand names Neurontin, Gralise, Horizant) or pregabalin (brand names Lyrica, Lyrica CR) who have respiratory risk factors. These include the use of opioid pain medicines and other drugs that depress the central nervous system (or CNS), and conditions such as chronic obstructive pulmonary disease that reduce lung function. The elderly are also at higher risk.

Gabapentin and pregabalin are FDA-approved for a variety of conditions, including seizures, nerve pain, and restless legs syndrome. Pregabalin is a Schedule V controlled substance, which means it has a lower potential for abuse among the drugs scheduled by the Drug Enforcement Administration but may lead to some physical or psychological dependence.

Our evaluation shows that use of these gabapentinoid medicines, has been growing for prescribed medical use, as well as misuse and abuse. Gabapentinoids are often being combined with CNS depressants, which increases the risk of respiratory depression. There is less evidence supporting the risk of serious breathing difficulties in healthy individuals taking gabapentinoids alone.

We are requiring new warnings about the risk of respiratory depression be added to the prescribing information of the gabapentinoids and have required the drug manufacturers to conduct clinical trials to further evaluate their abuse potential, particularly in combination with opioids. Misuse and abuse of these products together is increasing and may increase the risk of respiratory depression.

Health care professionals should start gabapentinoids at the lowest dose and monitor patients for symptoms of respiratory depression and sedation when co-prescribing with an opioid or other CNS depressant as pairing an opioid with any CNS depressant will increase the risk of respiratory depression.

We reviewed several sources of data, including case reports submitted to FDA or published in the medical literature, observational studies, clinical trials, and animal studies. Among 49 case reports submitted to FDA from 2012 to 2017, 12 people died from respiratory depression with gabapentinoids, all of whom had at least one risk factor.

Side effects involving gabapentin, pregabalin, or other medicines should be reported to FDA’s MedWatch program at www.fda.gov/medwatch.

A link to the full communication detailing specific information for health care professionals and the complete Data Summary can be found at www.fda.gov/DrugSafetyCommunications. If you have drug questions, you can reach us at druginfo@fda.hhs.gov

And follow us on Twitter @FDA_Drug_InfoExternal Link Disclaimer. Thank you for listening.

Related Information

  • FDA Drug Safety Communication: FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR)
  • FDA Drug Safety Podcast: FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR)

【来源】
FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR)

取自“https://lib.shilinx.com/wiki/index.php?title=FDA%E8%AD%A6%E5%91%8A%E7%94%A8%E4%BA%8E%E6%B2%BB%E7%96%97%E7%99%AB%E7%97%AB%E7%9A%84gabapentin%E5%92%8Cpregabalin%E5%8F%AF%E8%83%BD%E5%BC%95%E8%B5%B7%E4%B8%A5%E9%87%8D%E7%9A%84%E5%91%BC%E5%90%B8%E9%97%AE%E9%A2%98”
上一页: 药业的_2010_年代:加速、创新和充满争议的十年
下一页: 全球政策和战略办公室—欧洲办公室
相关内容
相关新闻
  • 国际检查会议与制药检查合作组...
  • 国际药品危机事件管理的法律、...
  • 国际药物工程管理(IPEM)课程...
  • 国际药物工程管理(IPEM)课程...
  • 国际检查互认不断拓展,菲律宾...
热点新闻
  • 【识林新工具】AI知识助手,AI...
  • 【直播】25年5月全球法规月报...
  • ICH 新 CTD:时隔23年,全新...
  • 【识林新文章】中国无菌附录对...
  • FDA 宣布扩大对国外生产设施...

 反馈意见

Copyright ©2011-2025 shilinx.com All Rights Reserved.
识林网站版权所有 京ICP备12018650号-2 (京)网药械信息备字(2022)第00078号
请登录APP查看
打开APP